Recent news highlights Grifols' FDA approval to launch Fesilty in the U.S. in early 2026, refinancing activities to extend debt maturities, and share price movements crossing below key moving averages.

• Grifols secured FDA approval to launch Fesilty in the U.S. in the first half of 2026, expanding its product portfolio in a key market [N8].
• The company completed a successful refinancing of its 2027 debt maturities via a Term Loan B credit agreement with tranches in USD and EUR and a revolving credit facility, improving liquidity and extending debt maturities [S2].
• Grifols shares crossed below the 200-day moving average in early 2026, noted in market technical analysis [N7][N5].

Grifols benefits from a growing global plasma protein market driven by population growth, new therapeutic indications, and geographic expansion. Its integrated platform and strategic partnerships enhance supply resilience and operational efficiency. The company’s disciplined R&D focus and expanding product pipeline support innovation. Recent refinancing efforts improve financial flexibility and liquidity. FDA approval for new products and expansion into emerging markets provide avenues for growth. Operational improvements in working capital and cost management contribute to profitability.

Grifols faces risks from regulatory changes, including pricing and reimbursement pressures, and tax uncertainties, particularly in Spain. The company’s finance costs have increased due to higher interest rates on new debt issuances. Market volatility and share price declines reflect investor concerns. Operational risks include maintaining plasma supply, managing inventory aging, and executing capital investments efficiently. Geopolitical and currency fluctuations may impact results. The company’s exposure to complex debt structures and refinancing needs presents financial risks.

Grifols' moat is anchored in its vertically integrated plasma platform, which provides supply security, operating leverage, and flexibility to respond to global demand and geopolitical shifts. The company's extensive network of plasma donation centers, regulatory approvals, and strategic partnerships in key markets create high barriers to entry. Its significant investments in manufacturing capacity, R&D pipeline, and compliance infrastructure further reinforce its competitive position. The plasma derivatives industry is highly regulated, requiring specialized expertise and capital, which limits new entrants and supports Grifols' market position.

• Regulatory and Pricing Risks: Grifols operates in a highly regulated industry with significant compliance costs. Changes in regulations or reimbursement rates, especially in the U.S., could impact operations and profitability.
• Tax and Legal Risks: The company faces increased tax provisions and assessments, notably in Spain, which have raised its effective tax rate and could affect future earnings.
• Financial and Debt Risks: Higher interest expenses on new senior secured bonds and complex debt structures increase finance costs and refinancing risks.
• Operational Risks: Maintaining plasma supply, managing inventory levels and aging, and executing capital expenditures efficiently are critical to operational performance.
• Market and Currency Risks: Fluctuations in foreign currency exchange rates and market volatility may affect financial results and investor sentiment.

• Grifols SA is a global healthcare company specializing in plasma-derived medicines and transfusion medicine, with a comprehensive portfolio including biological supplies, clinical diagnostic technologies, and medical tools and services.
• The company operates the world's largest network of plasma donation centers, with close to 400 centers across North America, Europe, Africa, the Middle East, and China.
• Grifols has more than 23,800 employees and operates in over 30 countries and regions.
• The company is listed on the Spanish Stock Exchange (IBEX-35) and its ADRs trade on NASDAQ under ticker GRFS.
• Grifols reported full-year 2024 revenue of approximately €7.2 billion and net income of €213 million, with basic and diluted EPS of €0.23 per share as of December 31, 2024.
• Research and development spending decreased slightly by 2.8% from €395 million in 2023 to €384 million in 2024, reflecting a more disciplined and focused approach on fewer, higher-priority projects.
• Selling, general and administrative expenses decreased by 8.6% from €1.4 billion in 2023 to €1.3 billion in 2024, driven by a 77.4% reduction in non-recurring reorganization costs.
• Finance costs increased in 2024 to a loss of €748 million from €574 million in 2023, mainly due to higher interest expenses on new senior secured bonds issued in 2024.
• The effective tax rate increased to 52.1% in 2024 from 19.3% in 2023, primarily due to extraordinary taxes related to the Shanghai RAAS transaction and increased uncertain tax provisions in Spain.
• As of December 31, 2024, Grifols had cash and cash equivalents of approximately €980 million, short-term investments of €244 million, current assets of €5.7 billion, and current liabilities of €2.2 billion, resulting in a current ratio of 2.66 and a cash ratio of 0.57.
• The company’s net cash from operating activities was €902 million in 2024 and increased to €1.0 billion in 2025, supported by strong operating results and efficient working capital management.
• Capital expenditures focus on expanding and enhancing production facilities, including plasma fractionation and immunoglobulin purification plants, with investments in the U.S., Canada, Egypt, and Europe.
• Grifols has a vertically integrated plasma platform in the U.S., spanning plasma collection, fractionation, purification, and commercialization, providing supply security and operating leverage.
• The company has strategic partnerships in Canada and Egypt to support local plasma self-sufficiency and regional plasma platforms, including Egypt achieving 100% self-sufficiency in key proteins in 2025.
• Grifols maintains a diversified product pipeline with 87 Biopharma initiatives and over 80 Diagnostic projects, including clinical studies for albumin, antithrombin, and immunoglobulin therapies.
• The company completed a refinancing in April 2026, including a Term Loan B credit agreement with tranches in USD and EUR and a revolving credit facility, aimed at extending debt maturities and improving liquidity.
• Grifols secured FDA approval to launch Fesilty in the U.S. in the first half of 2026, expanding its product offerings in the U.S. market.
• The company’s shares crossed below the 200-day moving average in early 2026, noted in market news.
• Grifols has implemented cybersecurity measures including ISO 27001 certification, network segregation, encryption, and user access controls to protect its digital infrastructure.
• The company’s business is subject to extensive regulation by FDA, EMA, and other authorities, requiring significant investments in compliant manufacturing and distribution facilities.
• Grifols sells receivables with and without recourse to financial institutions, with €1.6 billion sold without recourse in 2025.
• The company’s working capital management improved in 2025, with inventory aging decreasing to 258 days and average collection period improving to 31 days.
• Grifols has a commitment to deleveraging and maintaining adequate liquidity through internally generated cash flows and disciplined capital allocation.
• The company’s principal liquidity and capital requirements include operating costs, capital expenditures, acquisitions, and debt service obligations.
• Grifols’ global plasma protein market is growing, driven by population growth, new indications, geographic expansion, and increased diagnosis and treatment rates.
• The company’s 2025 net profit was €500 million, with total comprehensive income of -€632 million due to translation differences and other comprehensive losses.
• Major shareholders include Deria S.L. with 15.2% voting rights and Scranton Enterprises B.V. with 8.4%.
• Grifols’ shares are held predominantly by U.S. investors (64.3% of shares held by U.S. record holders).